Skip to main content

Key Product Details

Species Reactivity

Human, Mouse, Rat, Porcine, Canine


CyTOF-ready, ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Simple Western, Western Blot



Antibody Source

Monoclonal Mouse IgG1 kappa Clone # VG1


BSA Free


1 mg/ml

Product Summary for VEGF Antibody (VG1) - BSA Free


Recombinant VEGF 189 protein.

Reactivity Notes

Use in Rat reported in scientific literature (PMID:34423682). Use in Porcine reported in scientific literature (PMID:32132871).


This VEGF Antibody (VG1) detects the 189, 165 and 121 isoforms of VEGF






IgG1 kappa

Scientific Data Images for VEGF Antibody (VG1) - BSA Free

Western Blot Analysis of VEGF in Human Kidney

Western Blot Analysis of VEGF in Human Kidney

Analysis of VEGF in human kidney protein using NB100-664.
Immunocytochemistry/Immunofluorescence Staining of VEGF in U87 Cells

Immunocytochemistry/Immunofluorescence Staining of VEGF in U87 Cells

U87 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB100-664 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.
Immunohistochemical Analysis of VEGF in Peritoneal Tissue Sections

Immunohistochemical Analysis of VEGF in Peritoneal Tissue Sections

Immunohistochemistry: VEGF Antibody (VG1) - BSA Free [NB100-664] - HPG induces less VEGF production, less myofibroblast differentiation and lower macrophage activation. The expression of VEGF, alpha-SMA and MAC387 in the peritoneal tissue sections was examined using a routine immunohistochemical method. Data were a typical microscopic view of the peritoneal tissue sections in each group. a VEGF was detected using mouse monoclonal anti-VEGF antibody from Novus. Left graph a typical microscopic view, Dark brown stain VEGF-expressing cells (pointed by red arrows), Bv blood vessels, M muscle, black small bar 10 um. Right graph VEGF-expressing cells per 200 um PM length in cross sections. Data were presented as mean +/- SD (n = 6) and were analyzed using t test. Image collected and cropped by CiteAb from the following publication ( licensed under a CC-BY license.

Applications for VEGF Antibody (VG1) - BSA Free

Recommended Usage

Immunocytochemistry/ Immunofluorescence








Western Blot

1-2 ug/ml
Application Notes
In IHC a dilution of 1:20-1:50 was used in an ABC method. However, depending on the staining conditions employed, we suggest that the final dilution should be determined by the user. We suggest an incubation period of 30-60 minutes at room temperature. High temperature treatment of formalin-fixed tissue sections using 1mM EDTA, pH 8.0 must be performed prior to the immunostaining. This antibody is CyTOF ready.
Simple Western reported by an internal validation. Separated by Size-All; matrix was 12-230 kDa.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 1 review rated 5 using NB100-664 in the following applications:

Published Applications

Read 90 publications using NB100-664 in the following applications:

Formulation, Preparation, and Storage


Protein G purified




BSA Free


0.02% Sodium Azide


1 mg/ml


The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: VEGF

Vascular endothelial growth factor (VEGF), also called VEGF-A and vascular permeability factor (VPF), is a secreted homodimeric glycoprotein belonging to the VEGF family with a role in stimulating angiogenesis and vasculogenesis (1,2). More specifically, VEGF-A secretion from most cell types contributes to promoting endothelial cell proliferation and migration, inhibiting apoptosis, increasing vascular permeability, and wound healing (1). The VEGF family consists of several members including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placenta growth factor (PLGF) (1-4). As a result of alternative splicing of the eight exon VEGFA gene, there are several VEGF-A protein isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length, with VEGF121 and VEGF165 being the two most expressed isoforms (1,5). Full length VEGF-A monomer has a 26 aa signal sequence plus a 206 aa (VEGF206) sequence, with a theoretic molecular weight (MW) of 27 kDa, containing VEGF receptor 1 (VEGFR1) and VEGR2 binding sites and heparin-binding domains (1-3,5,6). VEGF121 lacks heparin affinity and binds the receptor tyrosine kinases (RTKs) VEGFR1 and VEGFR2, whereas VEGF165 has moderate affinity for heparin and, in addition to being a ligand for VEGFR1 and VEGFR2, can also bind the co-receptors neuropilin 1 (NRP1) and NRP2 (1,5). Hypoxia and hypoxia-related genes such as HIF-1, EGF, and PDGF are major regulators angiogenesis and VEGF expression (1,3). VEGF signaling initiated by ligand binding to its receptors results in activation of different pathways including PI3K and MAPK and ultimately guides endothelial cell proliferation, migration, and survival (1,3). While VEGF plays an important role in promoting normal angiogenesis and blood vessel formation, its expression is often upregulated in tumors and other angiogenesis-related pathologies like osteroarthritis (OA) (1-5,7). Given its function, VEGF and its receptors have become a therapeutic target for treating cancer and blocking angiogenesis (4,5,7). A recombinant humanized monoclonal anti-VEGFA antibody called bevacizumab (Avastin) was first approved by the FDA in 2004 for the treatment of a number of cancers (1-3,5). Cancer patients may experience resistance to anti-VEGF antibodies and, as such, clinical studies are exploring combination treatment options with chemotherapies and immune-checkpoint inhibitors (3,5).


1. Melincovici CS, Bosca AB, susman S, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455-467.

2. Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. Biomolecules. 2020;10(12):1673.

3. Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248-1264.

4. Matsumoto K, Ema M. Roles of VEGF-A signalling in development, regeneration, and tumours. J Biochem. 2014;156(1):1-10.

5. Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int J Mol Sci. 2018;19(4):1232. Published 2018 Apr 18. doi:10.3390/ijms19041232

6. Uniprot (P15692)

7. Hamilton JL, Nagao M, Levine BR, Chen D, Olsen BR, Im HJ. Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. J Bone Miner Res. 2016;31(5):911-924.

Long Name

Vascular Endothelial Growth Factor

Alternate Names

MVCD1, VAS, Vasculotropin, VEGF-A, VEGFA, VPF

Entrez Gene IDs

7422 (Human); 22339 (Mouse); 83785 (Rat)

Gene Symbol



Product Documents for VEGF Antibody (VG1) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for VEGF Antibody (VG1) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.


FAQs for VEGF Antibody (VG1) - BSA Free

Showing  1 - 5 of 5 FAQs Showing All
  • Q: I would be very grateful if you could let me know a recommended dilution for the VEGF antibody antibody NB100-664

    A: The recommended dilution for IHC is 1:20-1:50 in an ABC method. If instead you are testing on cell culture, I would recommend a starting optimization point of 1:10 -1:2000.

  • Q: I would like to know the aproximate dilution of the VEGF Antibody (NB100-664) to use it in a Western blot assay.

    A: In regards to your inquiry about our VEGF antibody (NB100-664), I am showing from the lab data that they have tested dilutions in the range of 1:500-1:1000 for this antibody. The optimal dilution should depend on your samples and the level of expression of VEGF, but a good starting point would be 1:1000 and then optimize from there.

  • Q: What is the minimum amount of protein necessary for the detection of VEGF by Western blot using VEGF Antibody (NB100-664)?

    A: I would suggest at minimum 10ug of protein per well but if you have enough sample you might want to run multiple wells with increasing amounts of protein to optimize the conditions in your hands. You could start with 5ug and do a couple of wells with 10ug, 20ug and 40ug. Also try using different dilutions of primary, start with 1:500-1:1000 and work your way up or down depending on what your blot looks like.

  • Q: I am interested in buying an antibody to VEGF to detect VEGF in human umbilical vein endothelial cells for western blotting and was wondering if you might have any recommendations? I was thinking about NB100-664. Do you have a recommended amount to use for western blotting? Could I ask you what concentration the antibody is at since it says 0.1mg so what total volume do you send? Also is this the most commonly purchase one for western blotting do you know?

    A: We do not have a recommended dilution noted for this specific antibody, but our general recommendation for Western blot is 1:1000-1:2000.This is a good starting point, but we always recommend optimization by the end user, as the optimal dilution is to some extent dependent on the particular sample/assay. The concentration for this product is stated as 1 mg/ml, so 0.1 mg would be supplied in 0.1 ml.

  • Q: I am looking for a VEGF-A antibody for the IHC staining of mouse colon. Do you have any publications or application references for this product?

    A: NB100-664 is one of our best sellers with great customer feedback and citations in at least 18 peer reviewed publications from highly esteemed researchers. As far as mouse tissues are concerned, I would recommend that you go through the following paper: Milanesi A, et al. Beta-Cell regeneration mediated by human bone marrow mesenchymal stem cells. PLoS One. 2012;7(8):e42177. doi: 10.1371/journal.pone.0042177. Epub 2012 Aug 7. PMID:22879915.

Showing  1 - 5 of 5 FAQs Showing All